The question of peptide safety cannot be answered with a single statement — because peptides is not a homogeneous category. It encompasses FDA-approved pharmaceuticals with extensive trial data (semaglutide, sermorelin), research peptides with robust preclinical and limited human data (BPC-157, TB-4), and experimental peptides with minimal published data.
FDA-Approved Peptides
FDA-approved peptide drugs have been through full drug approval: Phase I safety, Phase II efficacy, Phase III randomized controlled trials. Their safety profiles are well-characterized through both clinical trials and post-market surveillance. This category has the highest confidence in safety assessment.
Research Peptides: The Evidence Gap
BPC-157, TB-4, AOD-9604, Ipamorelin, and CJC-1295 have extensive preclinical research, some human clinical trial data, and substantial anecdotal use. What the research consistently shows: no significant toxicity at therapeutic doses, no carcinogenic findings, no hormonal suppression, and no significant drug interactions identified. This does not mean definitively safe over decades — it means the available evidence is favorable and no concerning signals have emerged.
Real Risks to Be Aware Of
Source quality: The most significant real-world risk is source quality. Non-pharmaceutical-grade peptides may contain endotoxins, incorrect sequences, or contamination. All PepLab peptide protocols use FDA-registered compounding pharmacies with verified quality control.
GH peptides and IGF-1: The theoretical concern is that elevated IGF-1 could stimulate cancer cell proliferation. This concern is mechanistic, not evidential — no study of therapeutic GH optimization has shown increased cancer incidence. Monitoring IGF-1 within physiologic ranges is the appropriate management approach.
Physician oversight: All peptide protocols benefit from baseline and follow-up lab monitoring, individualized dose selection, quality-controlled sourcing, and the ability to identify and respond to unexpected effects.